ANA Investigates American Neurological Association

Football fans may remember in January 2023 when Damar Hamlin, a player for the Buffalo Bills, suffered a cardiac arrest and collapsed on the field during a game on live television. He had a remarkable neurologic recovery, prompting us to focus our podcast that month on the need to avoid nihilism when we prognosticate after cardiac arrest. But what is the right balance between pessimism and optimism? Today, we'll hear from Dr. Karen Hirsch, neuro intensivist and associate professor of neurology at Stanford, about finding the Goldilocks zone in neuro prognostication after cardiac arrest. Dr. Hirsch was interviewed by Dr. Sarah Stern-Nezer, vascular neurologist and neuro intensivist at UC Irvine. Series 5, Episode 7
Featuring:
Guest: Dr. Karen Hirsch, Stanford Health Care Interviewer: Dr. Sara Stern-Nezer, University of California, Irvine Disclosures: None

Glioblastoma is the most common malignant brain tumor and one of the most aggressive solid tumors. Much progress has been made in the understanding and classification of gliomas, but progress in terms of prolonging survival has been limited. Several recent investigational therapies are bringing new hope. Our guest today is Dr. Eric Wong from Brown University. He is an international expert on advanced treatments for glioblastoma and a Professor of Medicine, Radiation Oncology, Neurosurgery, and Neurology at Brown University. He was interviewed by Dr. Christoph Stretz, a Vascular and Critical Care neurologist at Brown. Series 5, Episode 6
Featuring:
Guest: Dr. Eric Wong, Brown University Interviewer: Dr. Christoph Stretz, Brown University

Brain death is one of the most controversial and ethically complex topics in neurology, but it's a regular part of our clinical practice. Late last year, a new set of guidelines was published that address some of the thorniest technical and ethical issues in the clinical determination of brain death. For this discussion, we are joined by Dr. Ariane Lewis, a professor in the departments of Neurology and Neurosurgery, as well as the director of the Division of Neurocritical Care at NYU Langone Medical Center, and Dr. Matthew Kirschen, an assistant professor of Anesthesiology and Critical Care at the hospital of the University of Pennsylvania and the Children's Hospital of Philadelphia. They were interviewed by Dr. Masoom Desai of the University of New Mexico. Series 5, Episode 5
Featuring:
Guests: Dr. Ariane Lewis & Dr. Matthew Kirschen Interviewer: Dr. Masoom Desai Disclosures: None

Small fiber neuropathy is one of those conditions in neurology that can feel frustratingly intangible. Even for patients with severe neuropathic pain and autonomic symptoms, in about half of cases, the usual lab testing doesn't reveal a cause. There's increasing evidence that autoimmunity may be a factor in some of these cases of idiopathic small fiber neuropathy, but how to test and who to treat with immunosuppression is less clear. Our guest today, Anne Louise Oaklander, is an Associate Professor of Neurology at Massachusetts General Hospital and an Assistant in Neuropathology. She's known for her work on small fiber neuropathies and in this episode we'll talk about new autoantibodies associated with small fiber neuropathy and where we are in treating this challenging condition. Series 5, Episode 4
Featuring:
Guest: Dr. Anne Louise Oaklander Interviewer: Dr. Adeline Goss Disclosures: None

The recent FDA approval of lecanemab, an amyloid-sequestering agent, has been hailed as a breakthrough in the treatment of Alzheimer disease. Critics of the drug have pointed to its cost, risks, and treatment burden. Now that lecanemab is being administered in clinics across the country - how is it changing the lives of people with Alzheimers and their families? Dr. Megan Richie, neurohospitalist at UCSF, spoke to Dr. Seth A. Gale, Co-Director of the Brain Health Program and Assistant Professor of Neurology at Harvard Medical School. Dr. Gale has been involved in creating the clinical program that is delivering lecanemab to patients at Brigham and Women’s Hospital and Massachusetts General Hospital, with the first patients receiving the drug this month. Series 5, Episode 3
Featuring:
Guest: Seth A. Gale, MD - Co-Director of the Brain Health Program, and Assistant Professor of Neurology at Harvard Medical School Interviewer: Megan Richie, MD - Neurohospitalist at UCSF and Chair of the ANA Education Innovation Committee Disclosures: Dr. Gale disclosed that he is a site Principal Investigator or Sub-Investigator (at Brigham and Women's Hospital) for several clinical trials in Alzheimer disease. Sponsors for those studies include Biogen, Eisai, Roche, Genentech, and Eli Lilly. I am on a scientific advisory board for MindAhead DE, with the opportunity for honoraria.

Chronic pain can be incredibly challenging -- for patients, of course, and also for their physicians. On this episode of ANA investigates, Dr. Adeline Goss talks to Dr. Prasad Shirvalkar of UCSF about a new possible strategy for treating chronic pain: deep brain stimulation. Series 5, Episode 2
Featuring:
Guest: Dr. Prasad Shirvalkar of UCSF Interviewer: Dr. Adeline Goss Disclosures: Dr. Shirvalkar disclosed that Medtronic Inc, donated devices for research, but no direct financial support